CXCL13 and neoplasm: The significant reduction in the tumor weight and volume of mice treated with tumor-antigen pulsed 1st Gen and 2nd Gen Engineered DCs suggests that the expression of transgenes (CD40L, CD93, and CXCL13) combined with antigen pulsing led to elevated immune activation, subsequently leading to therapeutic efficacy.